70
Participants
Start Date
April 22, 2018
Primary Completion Date
August 31, 2020
Study Completion Date
August 31, 2020
Ismigen
Sublingual tablets containing 7 mg of bacterial lysate from the following bacteria: Staphylococcus aureus, Haemophilus influenzae serotype B, Klebsiella pneumoniae, Klebsiella ozaenae, Neiserria catarrhalis, Streptococcus viridans, Streptococcus pyogenes, Streptococcus pneumoniae (6 strains: TY1/EQ11, TY2/EQ22, TY3/EQ14, TY5/EQ15, TY8/EQ23, TY47/EQ24) - sublingual use 1 tablet per day over 10 days for 3 successive months.
Placebo
Matched tablets without any active substance.
Department of Pulmonary Diseases and Children Rheumatology, Medical University of Lublin, Lublin
Medical University of Lublin
OTHER